Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 139 |
| Active Pipeline (Recruiting Now) | 69 (49) |
| Completed vs Stopped Early | 39 / 30 (21.6%) |
| Median Closed Actual Enrollment | 30 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Stanford Health Care and Stanford Cancer Institute | Stanford, CA | 124 |
| Oregon Health and Science University Knight Cancer Institute | Portland, OR | 6 |
| University of Pennsylvania Abramson Cancer Center | Philadelphia, PA | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05121324 | Pediatric Dose Optimization for Seizures in Emergency Medical Services | Phase III | RECRUITING |
| NCT04355767 | Convalescent Plasma in Outpatients With COVID-19 | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Stanford University Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.